Jeffrey's mailing address filed with the SEC is C/O METACRINE, INC., 4225 EXECUTIVE SQUARE, SUITE 600, SAN DIEGO, CA, 92037.
Over the last 4 years, insiders at Metacrine have traded over 5,582,700$ worth of Metacrine stock and bought 11,645,167 units worth 119,461,162$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of 237,397$. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth 43,892$.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine executives and other stock owners filed with the SEC include: